SPDR S&P Biotech (XBI) 64.33 $XBI Shareholder Alert: 4

New Post Public Reply Private Reply Replies (0) Message Board

Oct 22, 2015 at 12:35 AM

SPDR S&P Biotech (XBI) 64.33 $XBI

Shareholder Alert: 4 Stocks Ready to Make a Move
ACCESSWIRE - Mon Oct 19, 11:17AM CDT
WINDSOR, ONTARIO / ACCESSWIRE / October 19, 2015 / The Wealthy Biotech Trader (or "WBT"

, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma, medical device and general healthcare stocks making news and subsequent market moves, is alerting traders about several trade ideas within the very healthy medical device sector.
LOXO: 23.60 (+0.87), XBI: 64.33 (+0.02), FORD: 1.18 (-0.02)

Watch for SPDR S&P Biotech ETF to Potentially Rebound After Falling 4.41% Yesterday
Comtex SmarTrend(R) - Tue Oct 13, 4:00PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $61.16 to a high of $65.20. Yesterday, the shares fell 4.4%, which took the trading range below the 3-day low of $61.38 on volume of 5.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
XBI: 64.33 (+0.02)

SPDR S&P Biotech ETF Down 7.4% Since SmarTrend Downtrend Call (XBI)
Comtex SmarTrend(R) - Tue Oct 13, 11:54AM CDT
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on September 25th, 2015 at $69.95. In approximately 3 weeks, SPDR S&P Biotech ETF has returned 7.38% as of today's recent price of $64.79.
XBI: 64.33 (+0.02)

Zacks Investment Ideas feature highlights: iShares Nasdaq Biotechnology, SPDR S&P Biotech ETF, ProShares Short S&P500, ProShares UltraShort S&P500 and ProShares UltraPro Short S&P500
Zacks Equity Research - Zacks Investment Research - Mon Oct 12, 8:30AM CDT
Zacks Investment Ideas feature highlights: iShares Nasdaq Biotechnology, SPDR S&P Biotech ETF, ProShares Short S&P500, ProShares UltraShort S&P500 and ProShares UltraPro Short S&P500
SPXU: 34.21 (+0.60), SH: 21.36 (+0.15), SDS: 20.92 (+0.27), XBI: 64.33 (+0.02), IBB: 304.46 (-1.50)

Protea: A High Quality Small-Cap to Ride Out Biotech's Drop
ACCESSWIRE - Mon Oct 12, 8:16AM CDT
REDONDO BEACH, CA / ACCESSWIRE / October 12, 2015 / The SPDR S&P Biotech ETF (ARCA: XBI) has fallen more than 20% over the past three months, which significantly outpaced the S&P 500's 4.7% fall over the same timeframe. With the House of Representatives subpoenaing Valeant Pharmaceuticals International Inc. (NYSE: VRX) for documents related to drug price increases, the market is concerned that the federal government may be stepping up its efforts to curb increases in drug prices.
VRX: 118.61 (-28.13), FMI: 22.07 (-0.40), XBI: 64.33 (+0.02), WAT: 121.34 (-0.67), VRX.TO: 154.21 (-36.64)

Juno Therapeutics (JUNO) Stock Could Lead the Way to a Biotech Bounce
at The Street - Fri Oct 09, 10:40AM CDT
We're watching the SPDR S&P Biotech ETF and its components for clues to a rally. Rejected lows in the charts have been encouraging.
XBI: 64.33 (+0.02), JUNO: 46.69 (-1.23)

Charting a Biotech Bounce
at The Street - Fri Oct 09, 10:10AM CDT
We're watching the SPDR S&P Biotech ETF for clues to a rally. Rejected lows in the charts have been encouraging.
XBI: 64.33 (+0.02), JUNO: 46.69 (-1.23)

7 Huge Mistakes Every ETF Investor Needs to Avoid
Eric Dutram - Zacks Investment Research - Fri Oct 09, 9:45AM CDT
These are some of the most common misconceptions about ETF investing, make sure you do not make the same mistakes!
SPY: 201.85 (-1.24), VXX: 20.29 (+1.34), GLD: 111.73 (-1.00), XBI: 64.33 (+0.02), IBB: 304.46 (-1.50), IAU: 11.27 (-0.11)

Correction in Health Care Stocks Remains in Full Force
at The Street - Thu Oct 08, 3:00PM CDT
Have we reached the point where something will be done about it?
CI: 136.61 (-5.60), ANTM: 142.79 (-5.45), HCA: 71.20 (-1.22), XBI: 64.33 (+0.02), UNH: 118.11 (-2.31), IBB: 304.46 (-1.50), XLV: 68.29 (-0.62)

3 Large-Cap Biotech Stocks Whose Valuations Should Make You Skeptical
Sean Williams, The Motley Fool - Motley Fool - Wed Oct 07, 7:03AM CDT
Source: Federal Reserve Bank of New York. With the exception of the last couple of weeks, the biotech sector has been a vast outperformer since the Great Recession. The broad-based S&P 500 has pretty much tripled since hitting its lows in...
BIIB: 276.34 (+10.53), VRTX: 109.62 (-0.63), XBI: 64.33 (+0.02), INCY: 107.15 (-0.35)

SPDR S&P Biotech ETF Rises 4.89% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Oct 02, 4:07PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $60.45 to a high of $65.75. Yesterday, the shares gained 4.9%, which took the trading range above the 3-day high of $64.56 on volume of 9.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
XBI: 64.33 (+0.02)

Biotech ETFs Looking Attractive After Sell-Off
Sweta Killa - Zacks Investment Research - Thu Oct 01, 7:55AM CDT
The current slide in biotech sector made the stocks valuation attractive at the current levels.
BBP: 28.82 (+0.02), SBIO: 28.07 (-0.21), XBI: 64.33 (+0.02), IBB: 304.46 (-1.50)

Top ETF Stories of September
Zacks Equity Research - Zacks Investment Research - Wed Sep 30, 12:34PM CDT
Inside the top financial stories of September and their impact on the world of ETFs.
73.92 (+0.23), KRE: 41.42 (-0.76), BBC: 26.84 (-0.09), SBIO: 28.07 (-0.21), VRX: 118.61 (-28.13), EWG: 26.33 (+0.07), IAI: 38.90 (-0.88), REM: 10.25 (-0.05), XBI: 64.33 (+0.02), EDV: 119.26 (+1.84), IBB: 304.46 (-1.50), GDX: 15.85 (-0.48)

Notable ETF Inflow Detected - XBI, ZIOP, ACHN, ZFGN
ETFChannel.com - Wed Sep 30, 9:52AM CDT
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF where we have detected an approximate $186.0 million dollar inflow -- that's a 10.1% increase...
XBI: 64.33 (+0.02)

Look for Shares of SPDR S&P Biotech ETF to Potentially Rebound after Yesterday's 7.19% Sell Off
Comtex SmarTrend(R) - Mon Sep 28, 4:09PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $61.28 to a high of $67.06. Yesterday, the shares fell 7.2%, which took the trading range below the 3-day low of $65.98 on volume of 14.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
XBI: 64.33 (+0.02)

Drug Pricing Fears Erase Biotech Stock Gains for the Year
at The Street - Mon Sep 28, 12:33PM CDT
The bloodletting in biotech stocks continued Monday with aggressive selling erasing the year's gains in a key sector exchange-traded fund. Another closely-followed ETF is barely hanging on to its outperformance.
BIIB: 276.34 (+10.53), VRX: 118.61 (-28.13), XBI: 64.33 (+0.02), IBB: 304.46 (-1.50)

Ill at Ease with Biotech? Prescribing #1 Healthcare ETFs
Zacks Equity Research - Zacks Investment Research - Mon Sep 28, 11:16AM CDT
Since the hot biotech ETF space appears to be on a correction mode, investors can invest in these better-insulated healthcare ETFs.
XHE: 44.53 (-0.14), SBIO: 28.07 (-0.21), BBC: 26.84 (-0.09), PSCH: 66.47 (-0.37), XBI: 64.33 (+0.02), IBB: 304.46 (-1.50), IHI: 116.56 (-0.28)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Minnesota Cremation Services Expands Reach Statewide

Compassionate Expansion Reflecting Community Needs You talk to just about any family facing the heart-wrenching task of making decisions for a loved one's final farewell, and the story ain't pretty. Pricey packages, pressure to upgrade, and a constant side-eye wondering if they're getting the real deal. For Minnesota Cremation Services, though, this expansion is about...

De¹ Unveils Tokenization Model on BNB Chain

De¹'s Bold Move into Enhanced Digital Finance Just when you thought the financial landscape couldn’t get any more complex, De¹ steps into the ring with its Tokenized Asset World on the BNB Chain—a move that's stirring the pot of tokenized finance in more ways than one. For old-school investors who thrive on waving outlandish stock bets, this crypto narrative is a...

Cruise Planners Sets AI Benchmark in Travel Innovs

Unveiling the AI Arsenal of Cruise Planners Alright, listen up, folks. When you think about travel and tech, Cruise Planners ain't just dipping a toe—they're cannonballing right in, splashing everyone around with their shiny new AI tricks. Twenty-three. That's how many innovations they're flaunting this year. It's like they're running a tech marathon, and boy, are they...

D2L Ventures into Vietnam with Van Lang Alliance

Unlocking New Frontiers in Vietnam's Education Well, looks like D2L is rolling into Vietnam with the kind of gusto you'd expect from a company that fancies itself a trailblazer in learning tech. This ain't just another humdrum expansion story; it's a five-year handshake with Van Lang Education Group that's got the tech firm dropping its anchor in a fresh and promising...

ITG Names Juliette Aiken CMO to Boost Storyteq's Reach

How do you put the throttle down on AI-driven content in a market that’s gasping for more? You bring in a heavyweight. Storyteq, the brainchild platform of Inspired Thinking Group (ITG), has roped in Juliette Aiken as their new Chief Marketing Officer. A veteran of the field, Juliette is tasked with propelling Storyteq from strong performer to an unbeatable force. New...

Sun Pharma's UNLOXCYT Gains NCCN Category 2A Nod

UNLOXCYT: A New Player in Cancer Treatment Well, here's a notch up for Sun Pharma. Their UNLOXCYT® (cosibelimab-ipdl) just got a Category 2A Preferred Designation from the NCCN for locally advanced cutaneous squamous cell carcinoma (laCSCC) patients who can't opt for surgery or radiation. And if you know anything about cancer treatment guidelines, you know that's a big...

Ruth E. Carter Returns Home with Celebrated Exhibition

Ruth E. Carter’s Triumphant Return When a titan of the costume design world circles back to their roots, you know it’s bound to be something special. Ruth E. Carter, who has swapped needles and threads for Oscars (twice, mind you), is making a return to Hampton University, paying homage to the very soil that sowed her artistic seeds. Ain't that a capstone of a career...

Tenet® Beef: Revolutionizing Tenderness in America's Steaks

Cracking the Code: A Genetic Leap in Beef Tenderness Well, buckle up, folks, because Callipyge Genetics is shaking things up in the beef aisle with their genomic breakthrough, Tenet®. It's about time we see some real innovation in an industry that's, let's face it, been slow to evolve. This isn't just a flash in the pan—a bit of DNA parsing has uncovered how to...

Shadeform's Spot: Monetizing Idle GPU Resources

Shadeform's Spot Aims To Cut GPU Waste Imagine letting money burn while your GPUs sit in idle mode. That's the reality for many in the cloud computing sector, and Shadeform looks ready to tackle this inefficiency head-on. The launch of Spot, by the GPU Cloud Marketplace Shadeform, offers a novel way to make sure every floating gigaflop translates into some form of...

Tripo AI's EdenLive Sparks Major Leap in Real-Time Rendering

Pushing Limits with EdenLive Tripo AI isn't just throwing a new gadget into the sea of tech; they're putting up a lighthouse. EdenLive, their blazing new real-time generative renderer, makes you re-think what on-the-fly animation can do. This ain't your average pixel pusher—it's a shot of adrenaline straight into the heart of interactive experiences. Let's chat Project...